Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
UROGEN PHARMA RG (NQ: URGN)
57.19 USD  -0.69 (-1.19%)
Official Closing Price  /  Updated: 5:20 PM EDT, Apr 19, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 334,960
Open 57.78
Bid (Size) 56.50 (100)
Ask (Size) 62.00 (600)
Prev. Close 57.88
Today's Range 55.81 - 58.98
52wk Range 13.01 - 66.38
Shares Outstanding 4,473,373
Dividend Yield N/A
Performance
YTD
+48.01%
+48.01%
1 Month
+7.42%
+7.42%
3 Month
+32.20%
+32.20%
6 Month
+104.76%
+104.76%
1 Year
+309.08%
+309.08%
Top News
More News
Factors of Influence in 2018, Key Indicators and Opportunity within Dorman Products, Arch Capital Group, Acacia Communications, UROGEN PHARMA, CyrusOne, and TCP Capital — New Research Emphasizes Econo
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Dorman Products, Inc.... Read More
from GlobeNewswire News Releases
UroGen Pharma Announces Presentation of Results from Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC)
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced a new... Read More
from GlobeNewswire News Releases
More News
Read More
Research Report Identifies Prothena, UROGEN PHARMA, Mizuho Financial Group, 1-800 FLOWERS.COM, Willis Towers Watson Public, and First Connecticut with Renewed Outlook — Fundamental Analysis, Calculati
from GlobeNewswire News Releases
UroGen Reports Fourth Quarter and Full Year 2017 Financial Results
from GlobeNewswire News Releases
UroGen Pharma to Report Fourth Quarter and Full Year 2017 Financial Results on Thursday, March 15, 2018
from GlobeNewswire News Releases
UroGen to Present at March 2018 Investor Conferences
from GlobeNewswire News Releases
UroGen Pharma Strengthens Management Team with the Appointment of Stephen Mullennix as Chief Operating Officer
from GlobeNewswire News Releases
Investment Opportunities in Advanced Bioengineered Drug Delivery
from PR Newswire
UroGen Pharma Announces Closing of Upsized Public Offering of Ordinary Shares and Full Exercise of Underwriters' Option
from GlobeNewswire News Releases
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares
from GlobeNewswire News Releases
Investment Opportunities in Advanced Bioengineered Drug Delivery
category PREV , PRVCF , VRX , and 5 more.
from NetworkNewsWire
Stock Market JSON API provided by www.cloudquote.net
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
X